Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas
2005 (English)In: Journal of Neuro-Oncology, ISSN 0167-594X, E-ISSN 1573-7373, Vol. 71, no 3, 325-332 p.Article in journal (Refereed) Published
The aim of the present study was to assess the usefulness of positron emission tomography (PET) as a surrogate endpoint by analysing the uptake variability of 11C-methionine (MET) in follow-up scans.
A total of 96 PET MET scans were re-evaluated in 32 patients with histologically confirmed supratentorial grade 2 gliomas.
In untreated patients, all follow-up PET scans showed an increased tumour volume after median 68 weeks, but only 46% of cases had an increased hot spot uptake. An improved outcome was observed in patients with stable hot spot uptake per se (P=0.07) and in combinations with minor increase in tumour volume (P=0.02). After conventional therapy, 52% of PET scans showed a reduced hot spot uptake the first year and 43% were reduced after more than a year. Successful MET decline after therapy did not correlate with outcome.
PET MET may be a promising surrogate endpoint after treatment of grade 2 gliomas. Evaluation of both hot spot activity and uptake volume on PET may strengthen the association with clinical outcome.
Place, publisher, year, edition, pages
2005. Vol. 71, no 3, 325-332 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-69557DOI: 10.1007/s11060-004-2031-5OAI: oai:DiVA.org:uu-69557DiVA: diva2:97468